Bristol-Myers Squibb’s Study on Oral Anticoagulants in Elderly NVAF Patients: Market Insights

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study.

Study Overview: Bristol-Myers Squibb is conducting a study titled ‘A Multicenter Prospective Observational Double Cohort Study to Evaluate the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Patients Suffering From NVAF.’ The study aims to gather real-world data on the factors influencing the use of oral anticoagulants in elderly Italian patients with non-valvular atrial fibrillation (NVAF) and assess the persistence of treatment after one year.

Intervention/Treatment: The study examines the use of oral anticoagulants (OAs) in two groups of NVAF patients: those who are administered OAs and those who are not. The purpose is to understand the clinical characteristics associated with OA use.

Study Design: This is an observational cohort study with a cross-sectional time perspective. It involves two cohorts of NVAF patients to evaluate the association between clinical characteristics and OA use.

Study Timeline: The study began on January 31, 2022, and is currently recruiting participants. The last update was submitted on December 15, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates.

Market Implications: The findings of this study could influence Bristol-Myers Squibb’s stock performance by providing insights into the use of OAs in a significant patient population. Positive results may enhance investor confidence and position the company favorably against competitors in the anticoagulant market.

Closing Sentence: The study is ongoing, and further details are available on the ClinicalTrials portal.

To learn more about BMY’s potential, visit the Bristol-Myers Squibb Company drug pipeline page.